0
Original Contributions |

Purkinje Cell Cytoplasmic Autoantibody Type 1 Accompaniments:  The Cerebellum and Beyond

Andrew McKeon, MD; Jennifer A. Tracy, MD; Sean J. Pittock, MD; Joseph E. Parisi, MD; Christopher J. Klein, MD; Vanda A. Lennon, MD, PhD
Arch Neurol. 2011;68(10):1282-1289. doi:10.1001/archneurol.2011.128.
Text Size: A A A
Published online

Objective  To investigate the full extent of Purkinje cell cytoplasmic autoantibody type 1 autoimmunity (classically associated with paraneoplastic cerebellar degeneration) from clinical, immunohistochemical, and neuropathological perspectives.

Design  Case series.

Setting  Mayo Clinics, 3 sites (Minnesota, Arizona, and Florida).

Patients  Of 133 138 patients tested over a 21-year period, 83 (0.06%) were identified as seropositive for Purkinje cell cytoplasmic autoantibody type 1 IgG.

Main Outcome Measures  The frequency of cerebellar and noncerebellar disorders and the clinical outcomes (neurological and oncological) of the patients.

Results  All patients were women. At initial presentation, 64 patients (77%) had a cerebellar disorder, and 19 patients (23%) had an extracerebellar disorder. Over the clinical course, neurological symptoms and signs were multifocal in 50 patients (60%), and they involved the cerebellum (89% of patients), the pyramidal tract (30%), the brainstem (13%), and the spinal anterior horn cells or peripheral nerve (10%; frequently upper limb predominant); 11% of patients did not develop cerebellar ataxia. Serological and neuropathological findings were observed in the cerebellum, the brainstem, the spinal cord, the anterior horn, and the dorsal root ganglion that paralleled the diversity of clinical signs. After a median follow-up of 18 months, 1 or more carcinomas had been detected in 88% of patients: ovarian epithelial cancer (53%), breast cancer (22%), fallopian tubal cancer (11%), primary peritoneal cancer (5%), metastases of unknown primary cancer (4%), and other cancers (4%). Sustained improvement was reported in 15% of patients following oncological or immunological therapies. Voltage-gated calcium channel antibodies coexisted in 23 patients (28%).

Conclusions  Purkinje cell cytoplasmic autoantibody type 1 autoimmunity most commonly affects the cerebellum, but the spectrum of neurological symptoms and presentations is broad. Neurological outcomes are usually poor, even when cancer remission is achieved.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Autoimmune myelopathy associated with Purkinje cell cytoplasmic autoantibody type 1 IgG. An axial T2-weighted magnetic resonance imaging scan of the cervical spine (C5 level) reveals bilateral symmetric signal abnormalities in the cord of a 66-year-old woman with motor neuronopathy (patient 7 in Table 1).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Distribution of Purkinje cell cytoplasmic autoantibody type 1 immunoreactivity in mouse neural tissues. Neural-specific staining was ensured by the absorption of bovine liver powder in serum samples (3 times at 1:240 or greater dilution).9 The patient's IgG binds to discrete cytoplasmic elements: A, Purkinje (P), molecular (M), and Golgi (G) neurons in the cerebellar cortex; B, cerebellar dentate neurons; C, the myenteric plexus and ganglionic neurons; D, hippocampal neurons; E, midbrain neurons; F, spinal cord neurons (SC), the nerve root (NR), and the dorsal root ganglion (DRG). Scale bars represent 40 μm (A-F).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 3. Representative images from brain and spinal cord findings in 2 autopsied cases (patient 9 [A-F] and patient 10 [G-I]). Neuropathology associated with Purkinje cell cytoplasmic autoantibody type 1 IgG is not restricted to the cerebellum. A, In the cerebellum, prominent loss of neurons in the Purkinje cell (PC) layer, between the molecular layer (ML) and the granular layer (GL), can be seen. White matter (WM) is gliotic (hematoxylin-eosin stain). B, In the cerebellum, Purkinje neurons (PC layer) are absent; WM gliosis is marked, and the GL is largely preserved (hematoxylin-eosin stain). C, In the pons, neuronophagia in the pontine tegmentum can be seen (hematoxylin-eosin stain). D, In the pons, gliosis and perivascular lymphocytic cuffs in the basis pontis can be seen (hematoxylin-eosin stain). E, In the lower medulla, microglial activation and marked gliosis can be seen (hematoxylin-eosin stain). F, In the thoracic cord, anterior horn neuronal loss and marked gliosis can be seen (hematoxylin-eosin stain). G, In the spinal cord (T8), CD3+ perivascular and parenchymal lymphocytes can be seen. H, In the spinal cord (T8), many perivascular and parenchymal lymphocytes are CD8+. I, In the L1 dorsal root ganglion, dense lymphocytic infiltrates can be seen (hematoxylin-eosin stain). Scale bars represent 250 μm (A-I).

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination
Make the Diagnosis: Cancer, Family History

The Rational Clinical Examination
Original Article: Does This Patient Have a Family History of Cancer?